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Backgrounds: Developmental pluripotency-associated 4 (Dppa4) gene plays an important role in self-renewal and
pluripotency sustainability in embryonic stem cells. It is re-expressed in several malignant tumors and is identified
as a new pluripotency-related oncogene. The present study investigates the expression and clinical significance of
Dppa4 in colon cancer.
Methods: Real-time polymerase chain reaction and Western blotting were used to evaluate Dppa4 mRNA and
protein expression in 39 pairs of fresh-frozzen colon cancer samples, which were compared with adjacent normal
mucosa. The Dppa4 protein was evaluated by immunohistochemical techniques using colon tissue microarrays
(TMA). The sample included 185 cancer specimens and corresponding normal colorectal mucosa. The effect of
Dppa4 knockdown on colorectal cancer cell proliferation was investigated using Cell Counting Kit-8 (CCK8) assays
and colony-formation assays.
Results: Both the mRNA and protein level expression of Dppa4 gene was found to be upregulated in colon cancer
tissues. Furthermore, the upregulated expression of Dppa4 was significantly correlated with the results of American
Joint Committee on Cancer (AJCC) stage (P = 0.01), invasion depth (P = 0.028), nodal involvement (P = 0.012), distant
metastasis (P = 0.003), and differentiation (P = 0.002). Dppa4 was also shown to be an independent prognostic indicator
of disease-free survival (HR 6.118, 95 % CI 3.004–12.462) and overall survival (HR 6.348, 95 % CI 2.875–14.014) for patients
with colon cancer. Knockdown of Dppa4 expression inhibited the proliferation of colorectal cancer cell lines through
G1/S transition regulation.
Conclusion: The results indicate that Dppa4 might play an important role in colon cancer progression and function as
a novel prognostic indicator and a potential therapeutic target.
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The relationship between cancer and stem cells is very
astonishing [1]. Recent research supports the idea that
human cancers can be considered as a stem cell disease
[2]. The cancer-initiating cells, also known as cancer stem
cells (CSCs), play an important role in hematopoietic can-
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creativecommons.org/publicdomain/zero/1.0/cancer [3–5]. According to the CSC hypothesis, cancer
cells with stem cell-like features such as self-renewal and
pluripotency sustains to have tumorigenic capacity [6, 7].
It seems that the molecular pathway of self-renewal in
normal stem cells is the same as that of CSCs in tumor
[8]. Many self-renewal regulatory factors, such as Oct4,
Sox2, Bmi, and Nanog, are re-expressed in human malig-
nant tumors, and they play an important role in carcino-
genesis [9, 10].
Developmental pluripotency-associated 4 (Dppa4) is
one of the uncharacterized genes that is highly expressed
in embryonic stem (ES) cells. It has been reported thatticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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Sox2 genes [11] and Dppa4 could modulate chromatin
structure in association with DNA and histone H3 in ES
cells [12]. In a study of expression of stem cell-specific
marker genes in multiple malignant tumors, Dppa4 was
found to be significantly expressed in cancer cell lines
and cancer tissues, including colon cancer and colorectal
cell lines [9]. Po-Yuan Tung [13] et al. found that Dppa4
is an oncogene in both mouse 3 T3 cells and immor-
talized human dermal fibroblasts (HDFs). In addition,
DPPA4 over-expression induces cell proliferation via
genes related to the regulation of G1/S transition. How-
ever, the clinicopathological significance of Dppa4, and
its possible mechanism in colon cancer tumorigenesis
and progression is still unclear.
The current study was aimed to access the expression
of Dppa4 at both transcriptional and translational levels
and its predictive value in colon cancer. We investigated
whether Dppa4 is an independent biomarker that could
predict metastasis and prognosis in patients with colon
cancer. By knockdown of Dppa4 expression with shRNA,
we also investigated the effects of Dppa4 on colon cancer
proliferation and its possible mechanisms.
Materials and methods
Patients and specimens
The study was conducted according to the Declaration
of Helsinki and approved by the Ethics Committee of
Shanghai Jiaotong University affiliated Shanghai First
People’s Hospital Medical Center. Written informed con-
sent was obtained from all patients. A total of 185 pairs of
samples were obtained from patients with primary colon
cancer who had undergone surgery without any preopera-
tive therapy at the Shanghai Jiaotong University affiliated
Shanghai First People’s Hospital Gastrointestinal Cancer
Center between January 2001 and December 2003. Fresh
samples were divided into two aliquots: One was snap-
frozen into RNA Keeper Tissue Stabilizer (Vazyme Biotech
Co., Ltd, Jiangsu, China), stored at 4 °C overnight, and then
transferred to −80 °C for long-term storage; and the other
was paraffin embedded for TMA construction. The diag-
nosis was confirmed by at least two pathologists. The
anatomical location of the primary tumor was categorized
as right, transverse, left, or sigmoid. Staging was based on
pathological findings according to the American Joint
Committee on Cancer (AJCC).
TMA construction and immunohistochemistry
TMA construction was undertaken as reported previously
[14]. Expression of Dppa4 was tested using standard im-
munohistochemical methods [15, 16]. The corresponding
primary antibodies used were as follows, Dppa4 (1:200 di-
lution, ABGENT, San Diego, CA) and Ki-67 (1:50 dilution,
Abcam, Cambridge, UK).Based on the intensity and extent of staining the immu-
nohistochemically stained slides were reevaluated by two
independent observers who were blinded to patient infor-
mation [17]. Briefly, Dppa4 cytoplasmic staining of the
invasive tumor cells was designated with an intensity score
(0 [no staining], 1 [weak staining], 2 [moderate staining],
and 3 [strong staining]) and an extent score (0 [no staining
of cells], 1 [<10 % of tissue stained positive], 2 [10 %–50 %
stained positive], 3 [>50 % stained positive]). The intensity
and extent score were then summed up to give a total
score ranging from 0 to 6, with a total score of 0 to 2, 3 to
4, and 5 to 6 defined as no expression, weak expression,
and strong expression of Dppa4. The Ki-67 proliferation
index was based on the percentage of cells with positive
nuclear staining and was divided into two groups: negative
(≤10 % of cells with positive nuclei) and positive (>10 % of
cells with positive nuclei).
Cell culture and reagents
Human colon cancer cell lines RKO, LoVo, HCT116,
SW480, SW620, HCT8, HT29, CaCo-2 were obtained
from the Type Culture Collection of the Chinese Academy
of Science (Shanghai, China) and cultured in Dulbecco’s
modified Eagle’s medium (DMEM, Hyclone, Logan, UT),
supplemented with 10 % fetal bovine serum (FBS, Gibco,
Australia) and 1 % penicillin-streptomycin (Gibco,) in a
humidified atmosphere containing 5 % CO2 at 37 °C.
Dppa4 knockdown plasmid construction and cell
transfection
To generate an effective Dppa4-shRNA oligonucleotide for
gene knockdown studies, 4 Dppa4-shRNAs were designed
and synthesized. The shRNA with the sequence 5’-
GCAAAGTTCTGAGACACAT-3’ was determined to be
the most effective shRNA in inhibiting Dppa4 expression.
The non-target shRNA sequence 5’-TTCTCCGAACGT
GTCACGT-3’ was employed as the negative control. The
specific double-stranded oligonucleotides were chemo-
synthesized, annealed, and then inserted into a shRNA
expression vector, GV248 (in collaboration with Shanghai
GeneChem Company, China). The Dppa4-shRNA and
negative control shRNA plasmids were transfected into
Caco2 and HCT8 cells using Lipofectamine 2000 (Life
Technologies, Rockville, MD). The Stable transfected cell
clones were selected in 2lg/ml puromycin-containing
medium (Sigma-Aldrich, St. Louis, MO). Dppa4 clone
expressions were confirmed by qPCR and Western blot
analysis.
Cell proliferation assay and colony formation assay
The effect of Dppa4 knockdown on colon cancer cell pro-
liferation was determined by measuring the absorbance at
450 nm. Briefly, untreated cells, cells treated with shRNA
or non-target shRNA were re-suspended and seeded into
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ing kit-8 (CCK-8, Dojindo Co., Kumamoto, Japan) was
added (10 μl) at 24, 48, and 72 h post-seeding. The
absorbance at 450 nm was measured 2 h later.
Colony-formation ability was evaluated by preparing
single-cell suspension solutions and then plating on a
6-well plate with 500 cells per well. After 14 days, the
developed colonies were stained with Gimesa for 20 min,
which were then counted and photographed. The tests
were independently performed in triplicates.
RNA extraction and real-time quantitative PCR
Total RNA was extracted from frozen tissue samples or
cultured cells using Trizol (Invitrogen Life Technologies,
Carlsbad, CA). After RNA intensity and purity was
checked, 3 μg of total RNA was reverse-transcribed into
the first strand of cDNA using the PrimeScript RT reagent
kit (Takara, Shiga, Japan). Then 1 μl cDNA was used as a
template for quantitative real-time PCR with SYBR Premix
Ex Taq II (Takara, Shiga, Japan) according to manufac-
turer’s instructions. Below mentioned are the specific
primers used: Dppa4, sense 5’- GACACAGATGGTTGG
GTTCA-3’ and antisense 5’-GAGGCAGGAAGCAAGAA
GAG-3’; GAPDH, sense 5’- AGAAGGCTGGGGCTCATFig. 1 Analysis of Dppa4 expression in human colon cancer tissues. a Dpp
detected by real-time PCR. Dppa4 mRNA level was normalized using GAPD
fold-change. b Western blot analysis was performed to access Dppa4 prote
adjacent noncancerous tissues (N). c Dppa4 protein is higher in tumor tissuTTG-3’ and antisense 5’-AGGGGCCATCCACAGTCTT
C-3’; Ki67, sense 5’-TTCGCAAGCGCATAACCCA-3’ and
antisense 5’-AACCGTGTCACAGTGCCAAA-3’; CCND1,
sense 5’-GCTGCGAAGTGGAAACCATC-3’ and antisense
5’-CCTCCTTCTGCACACATTTGAA-3’; TAF10 sense 5’-
CATTATCATGGGCCGACTCAAT-3’ , antisense 5’-TGTG
TAATCCTCCAACTGCATC-3’. GAPDH was used as the
internal control. Each reaction was performed in triplicates.
The relative DPPA4 mRNA expression was calculated by
2-ΔΔCt comparative method.
Western blot analysis
Total protein was isolated from tissue samples or cultured
cells using RIPA lysis buffer and then quantified by the
BCA assay kit (Beyotime Biotechnology, Jiangsu, China).
Each 30 μg total protein was electrophoresed on 10 %
SDS-polyacrylamide gel and then transferred to polyviny-
lidene fluoride (PVDF) membranes (Millipore, Billerica,
MA). These membranes were blocked using 5 % non-fat
milk with 0.1 % Tween 20 at room temperature for 1 h,
followed by incubation with the appropriate primary anti-
bodies: Dppa4 (1:500 dilution, ABGENT, San Diego, CA)
and β-actin (1:1000 dilution, Abcam, Cambridge, UK) at
4 °C overnight. Following incubation with a horseradisha4 mRNA levels in 39 primary tumor tissues and paired normal tissues
H expression. A logarithmic scale of 2-ΔΔCT was used to represent the
in levels in 8 representative cases of colon cancer samples (T) and
es than in paired adjacent normal mucosa
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tion, Santa Cruz Biotechnology, USA), the blots were visu-
alized by Immobilon Western Chemiluminescent HRP
Substrate (Millipore, Billerica, MA) according to the man-
ufacturer’s instructions. β-actin was used as the loading
control. Each sample was loaded in triplicate.
Statistical analysis
The differences between two groups were compared
with the t test, χ2 test, or Fisher’s exact test, as appropri-
ate. The patients’ survival curve was analyzed using the
Kaplan-Meier method with the log-rank test. A Cox pro-
portional hazards model was used to calculate univariate
and multivariate hazard ratios for the variables. All ana-
lyses were carried out using the SPSS 19.0 software
(SPSS Inc., Chicago, IL). All statistical analyses were set
to a significance level of 0.05.Fig. 2 Immunohistochemical staining of Dppa4 expression in tissue microarr
(b) Diffuse, intense Dppa4 staining in moderately and poorly-differentiated colo
200 (×50 for inserts). (d) Dppa4 expression in 185 cases of paired normal colon
(LNM). Dppa4 expression was significantly higher in LNM than in primary colonResults
Clinical information
Specimens were collected from 185 patients (79 men
and 106 women) with an average age of 65.82 years
(range, 22–95 years). Patient follow-up was carried out
for 177 patients who had undergone curative operations
according to the National Comprehensive Cancer Network
Practice Guidelines in colon cancer (Engstrom PF.2005;
3:468-91). Disease-free survival (DFS) and overall survival
(OS) rates were confronting each other, as per the interval
from the initial surgery to clinically or radiologically
proven recurrence/metastasis and death, respectively. The
final follow-up was on June 29, 2008, with a median pa-
tient follow-up time of 60 months (range, 10–89 months).
At the last follow up, 127 patients were still alive, whereas
50 had died, and 64 of the 177 patients experienced
recurrence.ays. a Negative-Dppa4 expression in normal colonic epithelium and
n tumors; (c) colon cancer lymph node metastasis. Original magnification ×
tissue, primary colon cancer and 63 cases of lymph node metastasis
cancer and normal colon tissue. (P< 0.001)
Table 1 Association between clinicopathological features and DPPA4 or Ki-67 protein expression
n DPPA4 expression P value
Negative (n = 62) (%) Weak (n = 54) (%) Strong (n = 69) (%)
Age, years (n,%) 0.423
<65 72 21 (33.9) 20 (37.0) 31 (44.9)
≥65 113 41 (66.1) 34 (63.0) 38 (55.1)
Gender (n,%) 0.519
Male 79 30 (48.4) 22 (40.7) 27 (39.1)
Female 106 32 (51.6) 32 (59.3) 42 (60.9)
Location (n,%) 0.650
Right 74 26 (41.9) 19 (35.2) 29 (42.0)
Transverse 18 7 (11.3) 6 (11.1) 5 (7.2)
Left 19 3 (4.8) 7 (13.0) 9 (13.0)
Sigmoid colon 74 26 (41.9) 22 (40.7) 26 (37.7)
T stage (n,%) 0.028*
T1 7 2 (3.2) 3 (5.6) 2 (2.9)
T2 21 10 (16.1) 7 (13.0) 4 (5.8)
T3 72 29 (46.8) 23 (42.6) 20 (29.0)
T4 85 21 (33.9) 21 (38.9) 43 (62.3)
N stage (n,%) 0.012*
N0 96 42 (67.7) 26 (48.1) 28 (40.6)
N1 58 16 (25.8) 18 (33.3) 24 (34.8)
N2 31 4 (6.5) 10 (18.5) 17 (24.6)
M stage (n,%) 0.003*
M0 168 60 (96.8) 52 (96.3) 56 (81.2)
M1 17 2 (3.2) 2 (3.7) 13 (18.8)
AJCC stage (n,%) 0.010*
I 22 11 (17.7) 6 (11.1) 5 (7.2)
II 71 29 (46.8) 20 (37.0) 22 (31.9)
III 75 20 (32.3) 26 (48.1) 29 (42.0)
IV 17 2 (3.2) 2 (3.7) 13 (18.8)
Differentiation (n, %) 0.002*
High 90 41 (66.1) 27 (50.0) 22 (31.9)
Moderate 68 17 (27.4) 20 (37.0) 31 (44.9)
Low 27 4 (6.5) 7 (13.0) 16 (23.2)
Vascular invasion (n, %) 0.420
Yes 173 60 (96.8) 50 (92.6) 63 (91.3)
No 12 2 (3.2) 4 (7.4) 6 (8.7)
Ki-67 index (n, %) 0.071
Negative 36 13 (21.0) 15 (27.8) 8 (11.6)
Positive 149 49 (79.0) 39 (72.2) 61 (88.4)
*P < 0.05 indicates a significant association among the variables
Zhang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:60 Page 5 of 11Dppa4 expression and activity in human colon cancer
The expression of Dppa4 in tumor tissue was examined
and compared with paired normal colonic mucosa in 39
patient samples using real-time PCR with GAPDH asthe internal reference. Among the 39 paired cases, 25
(64.1 %) colon cancer tissues showed at least a 2-fold in-
crease in Dppa4 mRNA level compared with its adjacent
non-cancerous mucosa (Fig. 1a). The average Dppa4
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5.17 ± 0.37 whereas in the normal tissue group, it was
8.90 ± 0.55 (P < 0.01), indicating that the Dppa4 mRNA
level was upregulated in cancer tissues than in paired
normal mucosa. Subsequently, Western blotting
showed a significant upregulation of Dppa4 protein
expression in cancerous colon tissue compared with
that of the corresponding normal tissue (2.44 ± 0.20 vs.
0.96 ± 0.06, respectively; P < 0.01, Student’s t-test)
(Fig. 1b and c).
The clinicopathologic significance of Dppa4 expression
was further determined by immunohistochemical analysis
on a tissue array containing 185 cases of primary colon
cancer paired with normal tissue and 63 cases of available
metastatic lymph nodes. As shown in Fig. 2, Dppa4 was
prominently localized in the cytoplasm of the cancer cells
and was prominently upregulated in 42.9 % (69 of 185) of
primary cancer specimens and 58.7 % (37 of 63) of LNM,
whereas the adjacent normal tissue was only 16.2 % (30 of
185), especially in cases with LNM. These results sug-
gested a possible role of Dppa4 involved in the metastasis
of colon cancer.
Association between Dppa4 immunoreactivity and
clinicopathologic variables are summarized in Table 1.
Dppa4 expression showed a positive result with the
American Joint Committee on Cancer (AJCC) stage
(P = 0.01), invasion depth (P = 0.028), nodal involve-
ment (P = 0.012), distant metastasis (P = 0.003), and dif-
ferentiation (P = 0.002).Fig. 3 Kaplan-Meier survival analysis of 5-year OS and DFS in 177 patients
poor OS and DFSHigh Dppa4 expression associated with poor clinical
outcome in human colon cancer
To assess the predictive role of Dppa4 for distant metasta-
sis, Kaplan-Meier curves with a log-rank test for OS and
DFS was undertaken in 177 patients who accepted radical
colectomy. There was a significant difference between
Dppa4-positive and Dppa4-negative groups after the
surgery (Fig. 3). Patients with Dppa4-positive tumors subse-
quently developed metastasis or local recurrence than those
with Dppa4-negative tumors (P < 0.01) [Dppa4-positive: 54
of 116 patients (46.6 %); Dppa4-negative: 10 of 61 (16.4 %)].
When compared with patients with Dppa4-negative tu-
mors, the DFS rate was significantly lower in patients who
had Dppa4-positive primary tumors (Fig. 3, log-rank test,
P < 0.001). Kaplan-Meier analysis also revealed that Dppa4
expression was significantly relevant to OS of colon cancer
patients (log-rank test, P < 0.001, Fig. 3). Patients with
Dppa4-positive tumors had a significantly lower 5-year OS
than those with Dppa4-negative tumors (57.8 % vs. 86.9 %).
In univariate analysis, patients with Dppa4-positively
stained colon tumors had an obviously lower DFS and OS
than those with Dppa4-negative tumors [DFS, HR 6.118
(95 % CI 3.004–12.462); OS, HR 6.348 (95 % CI 2.875–
14.014)] (Table 2). In addition, pT stage, pN stage, AJCC
stage, tumor differentiation, vascular invasion and Ki-67
index was correlated with OS and DFS. In multivariate
analysis with clinicopathologic parameters, the expression
of Dppa4 was found to be an independent prognostic
marker to predict tumor recurrence (Table 3).with colon cancer. Dppa4 expression was dramatically correlated with
Table 2 Univariate Cox proportional hazards model for overall survival (OS) and disease-free survival (DFS)
DFS OS
HR 95 % CI P-value HR 95 % CI P-value
Age, years
<65 — —
≥65 1.100 0.660–1.834 0.714 0.934 0.530–1.644 0.812
Gender
Male
Female 1.013 0.617–1.662 0.960 1.546 0.860–2.776 0.145
Tumor location
Right — —
Transverse 0.816 0.309–2.155 0.681 0.789 0.267–2.334 0.669
Left 1.392 0.619–3.130 0.423 1.291 0.512–3.252 0.589
Sigmoid colon 1.250 0.718–2.176 0.431 1.145 0.614–2.135 0.671
T stage
T1 0.494 0.119–2.049 0.331 0.988 0.299–3.259 0.984
T2 0.203 0.063–0.660 0.008* 0.394 0.138–1.130 0.083




N1 5.887 3.025–11.456 <0.001* 4.157 2.009–8.602 <0.001*
N2 15.914 7.781–32.545 <0.001* 13.193 6.149–28.307 <0.001*
AJCC stage
I — —
II 1.108 0.305–4.027 0.877 0.667 0.201–2.215 0.508
III 6.823 2.097–22.199 0.001* 3.401 1.184–9.771 0.023*
IV 49.185 12.615–191.764 <0.001* 40.074 11.257–142.668 <0.001*
Differentiation
High — —
Moderate 1.315 0.750–2.306 0.340 1.458 0.764–2.780 0.253
Low 3.577 1.885–6.786 <0.001* 4.358 2.140–8.872 <0.001*
Vascular invasion




Weak 1.931 0.748–4.985 0.174 0.794 0.308–2.051 0.634
Positive 2.667 1.203–5.913 0.016* 1.175 0.592–2.335 0.645
DPPA4 expression
Negative — —
Weak 2.598 1.194–5.653 0.016* 2.117 0.862–5.196 0.102
Positive 6.118 3.004–12.462 <0.001* 6.348 2.875–14.014 <0.001*
*P < 0.05 indicates a significant association among the variables
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Table 3 Multivariate Cox proportional hazards model for OS and DFS
DFS OS
Variable HR 95 % CI P-value HR 95 % CI P-value
DPPA4 expression 2.826 1.920–4.159 <0.001* 2.664 1.721–4.123 <0.001*
T stage 1.692 1.128–2.538 0.011* 3.989 1.754–9.073 0.001*
N stage 3.709 2.053–6.699 <0.001* 3.313 1.773–6.193 <0.001*
M stage 4.352 1.303–14.542 0.017* 8.000 2.393–26.745 0.001*
Ki-67 expression 1.226 0.790–1.904 0.363 1.570 0.846–2.914 0.153
*P < 0.05 indicates a significant association among the variables
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of colon cancer cells
To examine the effect of Dppa4 on colon cancer, a series
of functional experiments related to cell proliferation were
performed. Quantification by qRT-PCR and Western blot
denoted that Dppa4 expression level was higher in HCT8
and CaCo2 than other cell lines (Fig. 4a, b). RNA interfer-
ence (RNAi) technology was carried out to access the role
of Dppa4 in colon cancer cells. The efficiency of shRNA-
mediated knockdown in HCT8 or CaCo2 cells was more
than 60 % (Fig. 4c, d). CCK-8 assays showed a significant
inhibition of cell growth in the Dppa4 shRNA group com-
pared with the control groups at 24-, 48-, and 72-h time
points (Fig. 4e). Colony formation assay showed that
Dppa4 knockdown inhibited cancer cell colonogenicity
compared with control groups (Fig. 4f).
The mRNA level of proliferation-related gene ki-67 and
G1/S transition related genes, CCND1 and TAF10 was
evaluated to confirm the effect of Dppa4 knockdown on
cancer cell proliferation. Compared with the control cells,
Dppa4 shRNA group showed a lower ki-67, CCND1, and
TAF10 expression (Fig. 4g).
Discussion
It has been noted for years that cancer cells and embryonic
stem (ES) cells share some common characteristics with
respect to self-renewal, proliferation, and indefinite growth
[18]. The possible explanation for this phenomenon is that
these cells share some common genes. It had been
reported that many important stem cell markers such as
Oct-4, Sox-2, and Nanog are highly expressed in cancer
tissues and cancer cells [19, 20].
In this study, we explored the expression pattern of
DPPA4 in colon cancer samples and cell lines. Our results
showed for the first time that (1) over-expression of Dppa4
was significantly associated with unfavorable clinicopatho-
logical variables and Dppa4 might be used as a novel
prognostic marker for colorectal cancer. (2) DPPA4 expres-
sion level was associated with cancer progression and
proliferation.
Dppa gene family is a cluster of five genes whose de-
velopmental expression patterns are similar to those of
Oct4 [21]. The expression of Dppa4 is restricted duringearly developmental stages and in germ cells including
primordial germ cells, gonads, and testis [22]. It has a
putative DNA-binding domain named SAP (Scaffold
attachment factor A/B, Acinus, and PIAS), which is found
in SAF-A/B, poly (ADP-ribose) polymerase, Ku70, PIAS,
and Acinus and is thought to be involved in chromosomal
organization including RNA processing, DNA repair, and
apoptotic degradation of chromatin [23]. It has also been
reported that Dppa4 is a nuclear factor that is associated
with active chromatin and also regulates differentiation of
ES cells into a primitive ectoderm lineage [24]. The struc-
ture and functions of Dppa4 in biology process indicate
the possible mechanism of Dppa4 in cancer progression
and it might be a potential therapeutic target. Dppa4
re-expression has been found in tissue samples of colon,
prostate, and bladder carcinomas as well as cancer cell
lines HT-29, Caco-2, HT-1376, LNCaP, and HepG2 [9].
Recently, Dppa4 was identified as a novel family of
pluripotency-related oncogene [13]. However, the prognos-
tic potential role of Dppa4 in human colon cancer and its
potential role in the pathogenesis and progression of colon
cancer still remain unclear.
Our results showed that Dppa4 expression was up-
regulated in cancerous colonic tissues compared with
normal epithelium at the transcriptional as well as trans-
lational level. Overexpression of Dppa4 was associated
with cancer progression and metastasis. Individuals with
Dppa4-positively stained tumors experienced shorter OS
and DFS, indicating Dppa4 as a novel prognostic bio-
marker of colon cancer outcome. Finally, by univariate
and multivariate Cox model analyses, we confirmed
Dppa4 to be an independent prognostic factor for DFS
and OS in colon cancer.
To further understand the role of Dppa4 in tumori-
genesis, shRNA was used to knockdown the expression
of Dppa4 in HCT-8 and CaCo2 cells. Then CCK8 and col-
ony formation assays were implemented, which revealed
that knockdown of Dppa4 inhibited cell proliferation
activity. The expression of ki-67, which is considered as a
proliferation-related gene, showed obvious slumps in
Dppa4 knockdown cells than control groups. It is reported
that overexpression of Dppa4 could alter the levels of
several major components in p53 signaling pathway,
Fig. 4 (See legend on next page.)
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Fig. 4 Dppa4 expression in cell lines and its knockdown inhibits cancer cell proliferation. a Dppa4 protein levels and (b) mRNA levels in 8
colorectal cancer cell lines. c Western blot analysis, and (d) real-time PCR analysis of Dppa4 expression in stable knockdown CaCo2 and HCT8
cell lines. e Effects of Dppa4 knockdown on proliferation was evaluated by Cell Counting Kit-8 assays and (f) plate colony formation assays.
g Real-time PCR analysis of proliferation related genes and G1/S transition genes. (* P < 0.05, *** P < 0.01)
Zhang et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:60 Page 10 of 11including E2F1, MDM2, CDKN1A (p21), TRP63, BAX,
APAF1, and GADD45A, and DPPA4 can induce cell pro-
liferation through genes (including CCND1, TAF10 and
E2F1, which is considered as putative G1/S related genes)
related to regulation of the G1/S transition [13]. We ex-
amined the expression of CCND1 and TAF10 by RT-PCR,
and found that mRNA levels of both the genes were sig-
nificantly downregulated in Dppa4 knockdown cells, indi-
cating that Dppa4 suppressed cancer cell proliferation
through the regulation of G1/S transition, demonstrating
that Dppa4 is a potential therapeutic target for colon
cancer.
Study limitations include the small scale of investi-
gated patients with relatively short follow-up time, lack
of overexpressed cancer cell lines and in vitro experi-
ment setting. Further studies are needed to explore the
role of increased Dppa4 expression in the early stage of
colon cancer and the mechanism of Dppa4 deregulation
in colon cancer and its relation with p53 pathway and
the regulation of cell cycle.Conclusions
In summary, the present study identified that the Dppa4
mRNA and protein expression was upregulated in the
colon cancer samples. Dppa4 overexpression was associ-
ated with poor OS and DFS of colon cancer patients.
Dppa4 was also a significant independent prognostic fac-
tor for colon cancer. Furthermore, knockdown of Dppa4
inhibited cell proliferation through the regulation to G1/S
transition. Therefore, Dppa4 is associated with malignant
transformation of colon cancer and is a potential target
for cancer prevention and treatment.
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